Important Safety Information
ARTISS (Fibrin Sealant (Human))
ARTISS is indicated to adhere autologous skin grafts to surgically prepared wound beds resulting from burns in adult and pediatric populations.
ARTISS is not indicated for hemostasis.
Do not inject ARTISS directly into blood vessels. Intravascular application of ARTISS may result in life-threatening thromboembolic events.
Do not use ARTISS in individuals with a known hypersensitivity to aprotinin.
ARTISS is made from human plasma. It may carry a risk of transmitting infectious agents, e.g., viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
Apply ARTISS as a thin layer. Excessive clot thickness may negatively interfere with the product's efficacy and the wound healing process.
Adverse reactions occurring in greater than 1% of patients treated with ARTISS were skin graft failure and pruritus.
Please see ARTISS Prescribing Information for full prescribing details. http://www.baxter.com/products/downloads/ARTISS_PI.pdf
Baxter Healthcare Corporation is the principal U.S. operating
subsidiary of Baxter International Inc. (NYSE: BAX). Baxter International
Inc., through its subsidiaries, assists healthcare professionals and their
patients with the treatment of complex medical cond
|SOURCE Baxter Healthcare Corporation|
Copyright©2008 PR Newswire.
All rights reserved